Hymecromone ( DrugBank: Hymecromone )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 94 | Primary sclerosing cholangitis | 1 |
94. Primary sclerosing cholangitis
Clinical trials : 148 / Drugs : 118 - (DrugBank : 39) / Drug target genes : 18 - Drug target pathways : 141
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05295680 (ClinicalTrials.gov) | November 2022 | 4/3/2022 | Oral Hymecromone to Treat Adolescents and Adults With Primary Sclerosing Cholangitis. | A Study of Oral Hymecromone to Treat Adolescents and Adults With Primary Sclerosing Cholangitis(HAAPS Study). | Primary Sclerosing Cholangitis | Drug: Hymecromone | Paul Bollyky | NULL | Not yet recruiting | 14 Years | 75 Years | All | 24 | Phase 2 | United States |